D. D. V. Hoff

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

D. V. Von Hoff, H. Oettle, A. Zimmermann, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical and clinical strategies for development of telomerase and telomere inhibitors.

E. Raymond, D. V. Von Hoff, S. Hilsenbeck, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.

R. Plummer, D. V. Von Hoff, V. Lock, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

J. Nemunaitis, D. V. Von Hoff, A. Dorr, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.

R. Elledge, D. V. Von Hoff, M. Villalona-Calero, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

G. Demetri, J. Ware, G. Shapiro, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.

M. Hidalgo, R. Korn, M. Borad, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.